Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 354.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 80,381 shares of the biopharmaceutical company’s stock after acquiring an additional 62,695 shares during the period. Assenagon Asset Management S.A. owned approximately 0.06% of Alnylam Pharmaceuticals worth $36,654,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SVB Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $27,000. Atlantic Union Bankshares Corp purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $30,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $37,000. Ameritas Advisory Services LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $42,000. Finally, AlphaQuest LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $43,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $396.04 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The firm’s fifty day simple moving average is $447.38 and its 200 day simple moving average is $409.21. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The firm has a market capitalization of $52.32 billion, a price-to-earnings ratio of 1,650.17 and a beta of 0.30.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,650 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at approximately $29,675,409.21. This represents a 19.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,328 shares of company stock worth $27,288,993 over the last 90 days. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. BMO Capital Markets boosted their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Royal Bank Of Canada raised their target price on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Truist Financial upped their price target on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the company a “buy” rating in a report on Friday, October 17th. Twenty-three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $477.44.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.